Merck Receives Positive EU CHMP Opinion for Welireg Combination
The EU CHMP issued a positive opinion for Welireg (belzutifan) with lenvatinib for adults with advanced clear-cell renal cell carcinoma following anti-PD-1/PD-L1 therapy.
The EU CHMP issued a positive opinion for Welireg (belzutifan) with lenvatinib for adults with advanced clear-cell renal cell carcinoma following anti-PD-1/PD-L1 therapy.